Queensland

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:1000 publications

Grant number: N/A

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $4,500,000
  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)
  • Principal Investigator

    Keith Chappel
  • Research Location

    Australia
  • Lead Research Institution

    University of Queensland
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Full length S-protein Molecular clamp (pre-fusion viral insertion proteins are stabilised using a sequence from HIV. This is applicable to type I and III glycoproteins). Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Illustrated step-by-step guide to stent-assisted coiling of wide-neck posterior inferior cerebellar aneurysm via a contralateral vertebral artery approach.

One-year survival after critical care as a decision basis for advance care directives in general medicine: Real word data analysis of 149,144 patients.

Is first-pass effect a meaningful metric to evaluate thrombectomy technologies?

Breath profiles in paediatric allergic asthma by proton transfer reaction mass spectrometry.

Untested, unlicensed, unregulated: prescribing and oversight issues in physician-assisted dying/suicide.

Generative AI without guardrails can harm learning: Evidence from high school mathematics.

Targeting Superoxide to Prevent Diuretic Resistance and Reduce Heart Failure Mortality.

Astrocytic abnormalities in brain-specific <i>Cacna1c</i>-deficient mice: Implications for BBB impairment in neuropsychiatric diseases associated with <i>CACNA1C</i> mutations.